Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients
Galectin research required to initiate clinical trials, subject to funding, will be based on internal development as opposed to a license as previously reported.
- Boston, MA-NH (1888PressRelease) April 11, 2020 - BIOXYTRAN, INC. (OTCQB:BIXT), announced today that it intends to internally develop a novel carbohydrate Galectin inhibitor as opposed to licensing intellectual from Dr. David Platt as previously reported on March 24, 2020. The Company’s management believes that this approach will enable Bioxytran to develop a stronger intellectual property portfolio.
https://uploads-ssl.webflow.com/5cd9cf5f4183373f6b248799/5e816a1a957e0adfc8334a8e_COVID-19%20Therapeutic%20%20%20V4.3%20%203_29_2020.pdf
Dr. David Platt, Chief Executive Officer, remarked, “After reviewing the research and progress since the filing of my patent in 2009, I believe that we can be more responsive to the immediate needs posed by COVID-19 by developing a new patent portfolio rather than depending on my prior efforts. As a result, we terminated our prior licensing arrangement. Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis, including influenza and SARS providing a strong foundation to the hypothesis that Galectin-1 may be implicated in COVID-19. Our new strategy should enable us to build on the new body of research to develop a stronger patent portfolio.”
Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis. The journal article titled Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis demonstrates how viral pathogenesis is dependent upon galectin-1 in preclinical studies. The article demonstrated the direct binding of galectin-1 to the influenza virus. Yang et. al. indicated that “intranasal treatment of galectin-1 could enhance survival of mice against lethal challenge with influenza virus by reducing viral load, inflammation, and apoptosis in the lung.” This galectin-1 treatment resulted in a survival benefit of the mice and indicated theoretical mechanisms of action (MOA) in humans.
The journal article titled Crystal Structure of Bovine Coronavirus Spike Protein Lectin Domain explored the evolution of the coronavirus N-terminal domains (NTDs) which are commonly referred to as coronavirus protein spikes. Guiguing Peng et. al. concluded that “Bovine coronavirus NTD shares structural folds and sugar-binding sites with human galectins and has subtle yet functionally important differences from protein-binding NTD of mouse coronavirus.” This study confirmed the linkage between the mouse coronavirus and humans. There is much evidence to show that the coronavirus can jump between species. Since this receptor is similar on both species there is a consensus among the Scientific advisory board that this will translate to efficacy in humans.
The 2015 article titled, Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies demonstrated the similarities between influenza and SARS. Dr Fang Li said “the following evolutionary scenario has been proposed for coronavirus S1-NTDs.
Through gene capture, ancestral coronaviruses might have acquired a host galectin, which would become the S1-NTD of their spikes. Consequently, coronaviruses would recognize sugar receptors for cell entry.” Analysis of the crystalline structures showed the linkage between influenza and SARS. COVID-19 is also known as SARS-CoV2 which is an indicative that it is a subspecies of SARS. The SARS virus has a “galectin fold” which in theory represents a binding spot on the virus for Bioxytran’s galectin-1 inhibitor.
“The journal articles provide a strong foundation that galectin-1 is implicated in COVID-19,” said CEO David Platt of Bioxytran Inc. and co-author of Galectin. “Galectin-1 was implicated in pathogenesis of the virus in mice. Further study showed that the mice share the same N-terminal domain as humans. There are also many similarities between SARS and COVID-19 because they share the similar N-terminal domain. Based on these linkages the scientific team at Bioxytran concluded that a galectin-1 inhibitor could bind to the coronavirus spikes and reduce viral load. With the proper funding the company could be in human trials shortly.”
While Bioxytran will continue its plan to develop a pipeline of anti-necrosis drugs designed to treat hypoxia and our core strategy remains intact, our plan is to obtain additional funding for a proprietary Galactin-1 viral inhibitor developed internally and file for expedited trials under new FDA guidelines.
About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The Company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain. Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics a red blood cell traveling to the brain. Since the molecule is designed to be 5,000 times smaller than red blood cells it is expected to penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. The MDX Viewer will be used in evaluation of the safety and efficacy of the BXT-25.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam